Biotronik announced publication of results from the BIOSCIENCE trial in the journal EuroIntervention. The study’s authors suggest the Orsiro hybrid drug-eluting stent (DES) may have an advantage over Xience Prime/Xpedition in treating ST-segment elevation myocardial infarction (STEMI) patients. STEMI is a potentially fatal type of heart attack caused by a prolonged obstruction of blood supply in the heart. Every year nearly 250,000 people experience STEMI heart attacks.

Women undergoing transcatheter aortic valve replacement (TAVR) have better survival rates than men at one year, according to a study published in Annals of Internal Medicine. These results are the opposite of those seen in surgical aortic valve replacement (SAVR), for which female sex has been shown to be associated with poorer outcomes.

At the Houston Aortic Symposium, W. L. Gore & Associates, Inc. (Gore) announced the U.S. Food and Drug Administration (FDA) approval of the Gore Excluder Iliac Branch Endoprosthesis (IBE). The approval makes it the first off-the-shelf aortic branch device approved in the United States and the only device indicated for the endovascular treatment of common iliac artery aneurysms or aortoiliac aneurysms.

Medtronic plc announced the first patients enrolled in the Evolut R FORWARD Clinical Study to evaluate performance outcomes using the CoreValve Evolut R System in everyday clinical practice.

Pacific Northwest Endovascular Conference (PNEC)

March 4, 2016 — Boston Scientific has received U.S. Food and Drug Administration (FDA) approval for the Acuity X4 quadripolar left ventricular (LV) leads.

Recent results from the Carotid Revascularization Endarterectomy versus Stenting Trial (CREST) are evidence that stenting will continue to remain competitive with surgical treatment, said an analyst with research and consulting firm GlobalData. CREST data has shown patients with severe carotid artery stenosis suffered similar rates of adverse events in both stenting and endarterectomy procedures.

W. L. Gore & Associates (Gore) announced the availability of a new 7.5 cm length of the Gore Viabahn Endoprosthesis with heparin bioactive surface. Gore developed this size in response to physician needs for certain clinical situations. The device is now available in six lengths: 2.5, 5, 7.5, 10, 15 and 25 cm.

Brain imaging may accurately identify patients likely to benefit from stroke clot removal instead of relying on the time since symptoms began as an indicator of treatment eligibility. The hypothesis was derived from research presented at the American Stroke Association's International Stroke Conference 2016.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now